prostate cancer

January 24, 2024

Long-term follow-up pinpoints side effects of treatments for prostate cancer patients

A 10-year follow up study of nearly 2,500 U.S. men who received prostate cancer treatment will help inform decision making in terms of treatments and side effects for a diverse population.

By Craig Boerner
October 31, 2023

Polygenic “scores” may improve cancer screening

Accounting for genetic variability in biomarkers not associated with cancer risk could avoid unnecessary diagnostic procedures, Vanderbilt researchers found.

By Bill Snyder
July 26, 2023

International workgroup of geneticists issues CHEK2 guidelines

International workgroup issues additional guidance on how to manage patients who carry inherited CHEK2 gene mutations that put them at a higher risk for cancer.

By Tom Wilemon
April 3, 2023

More U.S. prostate cancer patients choosing active surveillance

A Vanderbilt study found the number of prostate cancer patients in the U.S. choosing active surveillance over surgery or radiation has rapidly increased since 2010, rising from 16% to 60% for low-risk patients and from 8% to 22% for patients with favorable intermediate-risk cancers.

By Craig Boerner
Research by Mingjian Shi, PhD, left, Jonathan Mosley, MD, PhD, Kerry Schaffer, MD, MSCI, and colleagues found that polygenic risk score does not improve prediction of aggressive prostate cancer.
March 16, 2023

Study evaluates polygenic risk score for prostate cancer risk prediction

A Vanderbilt study found that prostate cancer polygenic risk score has limited utility for enhancing prostate cancer screening.

By Leigh MacMillan
October 27, 2022

Study reveals pathways for aggressive prostate cancer subtype

Research from Vanderbilt-Ingram Cancer Center has revealed new information about the molecular pathways of cribriform prostate cancer.

By Tom Wilemon
August 4, 2022

Clinic helps patients prepare to move beyond prostate cancer

Vanderbilt's REACH for Survivorship Clinic takes a holistic approach to help treat prostate cancer patients.
By Craig Boerner
December 9, 2021

Prostate cancer treatment regret

Vanderbilt researchers suggest that to reduce treatment-related regret for men with localized prostate cancer, treatment preparation should focus on shared decision-making and aligning patient expectations with treatment toxicity.
By Leigh MacMillan
October 19, 2021

Combo therapy slows prostate cancer

A new combination treatment showed promise in slowing the growth of castration-resistant prostate cancer in animal models, Vanderbilt researchers discovered.
By Leigh MacMillan
September 23, 2021

Clinical trial tests ATR inhibitor in difficult-to-treat cancers

By Doug Campbell
June 22, 2021

Treating metastatic prostate cancer

An indirect comparative effectiveness study using published data suggests that the targeted therapy olaparib should be re-evaluated for treating metastatic prostate cancer.
By Leigh MacMillan
March 23, 2021

Prostate cancer microenvironment

Distinct cancer-associated fibroblasts in the prostate tumor microenvironment may influence tumor progression and could point to new therapeutic targets.
By Leigh MacMillan
September 17, 2020

New predictors of prostate cancer risk

An international group of researchers including Vanderbilt epidemiologists has identified new DNA methylation biomarkers associated with prostate cancer risk.
By Sarah E. Glass
1 2 3 4